Ocular Therapeutix (NASDAQ:OCUL) Issues Earnings Results

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05), Zacks reports. The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL traded up $0.19 during trading on Thursday, hitting $7.34. 1,504,273 shares of the company traded hands, compared to its average volume of 1,562,781. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.56 and a beta of 1.22. The business's fifty day moving average is $7.78 and its 200-day moving average is $8.88. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a one year low of $4.06 and a one year high of $11.78.

Insiders Place Their Bets

In related news, insider Donald Notman sold 6,301 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the sale, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,895 shares of company stock valued at $283,772 over the last three months. Company insiders own 3.50% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.